Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of RO7200220 plus ranibizumab versus ranibizumab alone in diabetic macular edema
MOH_2022-02-17_010494Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic macular edema (DME) comparing RO7200220 plus ranibizumab with Ranibizumab active control (2 arms). Primary endpoint: Primary efficacy endpoint. Started Feb 2022; status: completed.
02
Drugs
vamikibartranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on MOH_2022-02-17_010494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-02-17_010494.